These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 1142892)
1. [Letter: Drug consultant--a salesman]. Britton S Lakartidningen; 1975 Jun; 72(25):2662-3. PubMed ID: 1142892 [No Abstract] [Full Text] [Related]
2. [Drug legislation 1976: cost analysis for the pharmaceutical industry]. Kopf R Internist (Berl); 1980 Jun; 21(6):333-8. PubMed ID: 7005170 [No Abstract] [Full Text] [Related]
3. Drug industry trying to change FDA's slow but sure policy. Demkovich LE Natl J (Wash); 1979 Jul; 11(29):1211-5. PubMed ID: 10242491 [No Abstract] [Full Text] [Related]
4. [The drug industry should be nationalized]. Thomasson J Vardfacket; 1980 May; 4(9):18. PubMed ID: 6903072 [No Abstract] [Full Text] [Related]
5. Knowledge is power: legislative control of drug industry trade secrets. O'Reilly JT Spec Law Dig Health Care (Mon); 1987 May; 8(15):7-31. PubMed ID: 10281981 [No Abstract] [Full Text] [Related]
6. Medical costs and the drug industry. Schwartz H Wall St J Midwest Ed; 1980 Apr; 60(132):22. PubMed ID: 10245744 [No Abstract] [Full Text] [Related]
8. [Drug committee: TCO will not take a stand on current drug production]. Olofsson C Vardfacket; 1979 Jan; 3(1):74-5. PubMed ID: 253517 [No Abstract] [Full Text] [Related]
9. Drug lag bad: drug lack worse. Br Med J; 1980 Mar; 280(6215):670. PubMed ID: 7363015 [No Abstract] [Full Text] [Related]
10. [Editorial: Drug value after marketing. Problems with the so-called phase 4]. Hvidberg E Ugeskr Laeger; 1976 Mar; 138(14):872-3. PubMed ID: 1265864 [No Abstract] [Full Text] [Related]
11. Antiarrhythmic drug approval--an industry perspective. Jacobs S Can J Cardiol; 1991; 7(1):45-6; discussion 49-50. PubMed ID: 2025792 [No Abstract] [Full Text] [Related]
12. [Towards a new drug management]. Hoffmann M; Ahlner J Lakartidningen; 1995 Oct; 92(41):3804, 3807. PubMed ID: 7564634 [No Abstract] [Full Text] [Related]
13. The drug approval process and the FDA. Schmidt AM Conn Med; 1975 Apr; 39(4):237-40. PubMed ID: 1149447 [No Abstract] [Full Text] [Related]
14. [New drug law in Denmark]. Stromnes B Tidsskr Nor Laegeforen; 1976 May; 96(15):895. PubMed ID: 936172 [No Abstract] [Full Text] [Related]
15. No relaxation on drug safety and efficacy. Russell AS; Grace M World Health Forum; 1993; 14(1):31-3. PubMed ID: 8439367 [TBL] [Abstract][Full Text] [Related]
16. [The admission of drugs in the Netherlands]. ten Ham M Ned Tijdschr Geneeskd; 1983 May; 127(22):968-71. PubMed ID: 6866153 [No Abstract] [Full Text] [Related]
17. Evaluation of drugs by the medical letter. Abramowicz M Am J Hosp Pharm; 1976 Jan; 33(1):71-3. PubMed ID: 1266869 [TBL] [Abstract][Full Text] [Related]
18. The emerging effects of the Drug Price Competition and Patent Term Restoration Act of 1984. Lewis RA J Contemp Health Law Policy; 1992; 8():361-78. PubMed ID: 10118987 [No Abstract] [Full Text] [Related]
19. Recent developments help the defense of drug companies in 10b-5 cases. Salpeter AN; Hutchins H Food Drug Law J; 1996; 51(3):345-53. PubMed ID: 11797711 [No Abstract] [Full Text] [Related]
20. The FDA's restrictions against prescription drug advertising: more hindrance than help. Lorman AJ Healthspan; 1991 Nov; 8(10):3-7. PubMed ID: 10114942 [No Abstract] [Full Text] [Related] [Next] [New Search]